Quantum-Si to Participate in the UBS Precision Medicine Frontiers Summit

Audio By Carbonatix

BRANFORD, Conn.--(BUSINESS WIRE)--Aug 8, 2025--

Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will be participating in the UBS Precision Medicine Frontiers Summit taking place at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA, August 13-14, 2025.

Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will be available for one-on-one meetings throughout the day on Thursday, August 14, 2025, and Jeff Hawkins will participate in the New Dimensions in Proteomics and Cellular Research panel on the same day from 8:15 – 8:50 AM Pacific Daylight Time.

About Quantum-Si Incorporated
Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250808859106/en/

CONTACT: Investors & Media

Jeff Keyes

Chief Financial Officer

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA CONNECTICUT

INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HARDWARE ONCOLOGY HEALTH TECHNOLOGY

SOURCE: Quantum-Si Incorporated

Copyright Business Wire 2025.

PUB: 08/08/2025 08:00 AM/DISC: 08/08/2025 08:00 AM

http://www.businesswire.com/news/home/20250808859106/en